Eliot Charles, MiroBio executive chairman
Looking to bolster immune checkpoint R&D, Gilead buys MiroBio as it takes next-gen checkpoint therapy to the clinic
While Gilead dropped disappointing data on its Arcus-partnered CD37 inhibitor Wednesday afternoon, the biopharma is making moves to cushion its immune checkpoint pipeline. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.